Effect of Combined Use of Ivermectin and Colchicine in COVID-19 Patients

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05246072

Enrollment

135

Registered

2022-02-18

Start date

2021-11-01

Completion date

2022-02-28

Last updated

2022-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

The aim of this study will be to investigate the efficacy of use of combination of Ivermectin and colchicine on severity and outcome Of COVID 19 infection.

Interventions

DRUGIvermectin + colchicine

In addition to the local standard of care for COVID 19 patients, the patient will receive Ivermectin + colchicine

DRUGColchicine

In addition to the local standard of care for COVID 19 patients, the patient will receive colchicine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Willing and able to provide written informed consent prior to performing study procedures. * Currently hospitalized and requiring medical care for non-sever COVID-19. * One or more of the following: (positive PCR test or positive antibodies) or (CT Chest consistent with COVID19 infection).

Exclusion criteria

* Tocilizumab use. * Mechanical ventilation * Requirement of oxygen supplementation \>8L/min on admission

Design outcomes

Primary

Measure	Time frame
length of oxygen requirement	3 months

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026